Results 1 to 10 of about 21,169 (256)

Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors. [PDF]

Biophys Rev, 2022
Prostate-specific membrane antigen (PSMA), also called glutamate carboxypeptidase II (GCP(II)), is a Zn-dependent metalloprotease that is known as a well prostate cancer indication and a potential targeting towards anti-cancer medicines and drug delivery.
Nikfarjam Z, Zargari F, Nowroozi A, Bavi O.   +3 more
europepmc   +3 more sources

Expression of Prostate Specific Membrane Antigen (PSMA) in Breast Cancer. [PDF]

Geburtshilfe Frauenheilkd, 2022
Abstract Background Prostate specific membrane antigen (PSMA) is a promising protein for breast cancer patients. It has not only been detected in prostate cancer but is also expressed by tumor cells and the endothelial cells of tumor vessels in breast cancer patients. PSMA plays a role in tumor progression and tumor angiogenesis.
Unger C, Bronsert P, Michalski K, Bicker A, Juhasz-Böss I.   +4 more
europepmc   +4 more sources

Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector. [PDF]

PLoS ONE, 2012
Human prostate tumor vaccine and gene therapy trials using ex vivo methods to prime dendritic cells (DCs) with prostate specific membrane antigen (PSMA) have been somewhat successful, but to date the lengthy ex vivo manipulation of DCs has limited the ...
Briana Jill Williams, Shilpa Bhatia, Lisa K Adams, Susan Boling, Jennifer L Carroll, Xiao-Lin Li, Donna L Rogers, Nikolay Korokhov, Imre Kovesdi, Alexander V Pereboev, David T Curiel, J Michael Mathis   +11 more
doaj   +5 more sources

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer. [PDF]

Int J Mol Sci, 2021
Theranostics, a combination of therapy and diagnostics, is a field of personalized medicine involving the use of the same or similar radiopharmaceutical agents for the diagnosis and treatment of patients. Prostate-specific membrane antigen (PSMA) is a promising theranostic target for the treatment of prostate cancers.
Plichta KA, Graves SA, Buatti JM.
europepmc   +4 more sources

Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. [PDF]

Curr Oncol Rep, 2021
Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) is a promising investigational treatment for metastatic castration-resistant prostate cancer (mCRPC). This review describes the available data with PSMA TRT.Conjugates used for PSMA TRT include antibodies or small molecules PSMA-radiolabeled with beta (most commonly 177Lu) or
Sun M, Niaz MJ, Niaz MO, Tagawa ST.
europepmc   +4 more sources

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?

Therapeutic Advances in Medical Oncology, 2021
Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most prostate cancer cells and to a lesser extent in normal tissues. Many vectors targeting this protein have been created over the past decade and numerous clinical studies
Anne-Laure Giraudet, David Kryza, Michael Hofman, Aurélie Moreau, Karim Fizazi, Aude Flechon, Rodney J. Hicks, Ben Tran   +7 more
doaj   +1 more source

Planar 99mTc-PSMA Imaging of Prostate Cancer in a Low-Resource Setting: A Series Report

World Journal of Nuclear Medicine, 2022
Objective Technetium-99m labeled prostate-specific membrane antigen (PSMA) single-photon emission computed tomography/computed tomography (SPECT/CT) is a suitable alternative to prostate-specific membrane antigen-positron emission tomography (PSMA-PET ...
A.T. Orunmuyi, A.A. Oladeji, E.U. Azodoh, O.A. Omisanjo, E.O. Olapade-Olaopa   +4 more
doaj   +1 more source

Incidental prostate-specific membrane antigen-avid meningioma detected on 68Ga–prostate-specific membrane antigen PET/CT

Radiology Case Reports, 2021
A 70-year-old gentleman with a history of Gleason score 7 (3 + 4) prostate adenocarcinoma was treated with radical prostatectomy with clear surgical margins. Postoperatively his prostate specific antigen was undetectable.
James Yuheng Jiang, MD, MMed (ClinEpi), Joshua Wei Liang Yip, MBBS, Christine Kang, MD, MMed (ClinEpi), Vu Hoang Tran, MD, Marco Enoch Lee, MD, Ken Le, MBBS, FRANZCR, Robert Mansberg, MBBS, FRACP, FAANMS   +6 more
doaj   +1 more source

Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment

Case Reports in Surgery, 2023
Prostate-specific membrane antigen positron emission tomography (PSMA PET) has been approved by the Food and Drug Administration (FDA) to identify prostate cancer in the setting of biochemical recurrence but can also identify other malignancies. 18F-PSMA
Lauren Hekman, Eva Napierkowski, Natalie C. Hartman, Jeffrey L. Ellis, Robert H. Wagner, Davide Bova, Maria M. Picken, Robert C. Flanigan   +7 more
doaj   +1 more source

Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge

Frontiers in Oncology, 2023
This is a case of [68 Ga]Ga-Prostate-specific membrane antigen (PSMA)-11 PET/CT in a 73-years old patient presenting high Prostate Specific Antigen (PSA) levels despite both multi-parametric magnetic resonance imaging (mpMRI) and 12-core saturation ...
Luigia Vetrone, Giulia Cuzzani, Riccardo Mei, Lucia Zanoni, Alessandro Bertaccini, Lorenzo Bianchi, Paolo Castellucci, Caterina Gaudiano, Alberta Cappelli, Francesca Giunchi, Stefano Fanti, Stefano Fanti   +11 more
doaj   +1 more source